71
IRUS Total
Downloads
  Altmetric

Neuroinflammation in schizophrenia: meta-analysis of in-vivo microglial imaging studies

File Description SizeFormat 
Suplementary material.docxSupplementary information195.59 kBMicrosoft WordView/Open
neuroinflammation_in_schizophrenia_metaanalysis_of_in_vivo_microglial_imaging_studies.pdfPublished version371.83 kBAdobe PDFView/Open
Title: Neuroinflammation in schizophrenia: meta-analysis of in-vivo microglial imaging studies
Authors: Reis Marques, T
Ashok, A
Pillinger, T
Veronese, M
Turkheimer, F
Dazzan, P
Sommer, I
Howes, O
Item Type: Journal Article
Abstract: Background Converging lines of evidence implicate an important role for the immune system in schizophrenia. Microglia are the resident immune cells of the central nervous system and have many functions including neuroinflammation, axonal guidance and neurotrophic support. We aimed to provide a quantitative review of in vivo PET imaging studies of microglia activation in patients with schizophrenia compared with healthy controls. Methods Demographic, clinical and imaging measures were extracted from each study and meta-analysis was conducted using a random-effects model (Hedge's g). The difference in 18-kDa translocator protein (TSPO) binding between patients with schizophrenia and healthy controls, as quantified by either binding potential (BP) or volume of distribution (VT), was used as the main outcome. Sub-analysis and sensitivity analysis were carried out to investigate the effects of genotype, ligand and illness stage. Results In total, 12 studies comprising 190 patients with schizophrenia and 200 healthy controls met inclusion criteria. There was a significant elevation in tracer binding in schizophrenia patients relative to controls when BP was used as an outcome measure, (Hedge's g = 0.31; p = 0.03) but no significant differences when VT was used (Hedge's g = −0.22; p = 0.29). Conclusions In conclusion, there is evidence for moderate elevations in TSPO tracer binding in grey matter relative to other brain tissue in schizophrenia when using BP as an outcome measure, but no difference when VT is the outcome measure. We discuss the relevance of these findings as well as the methodological issues that may underlie the contrasting difference between these outcomes.
Issue Date: 25-Oct-2018
Date of Acceptance: 25-Sep-2018
URI: http://hdl.handle.net/10044/1/63327
DOI: https://doi.org/10.1017/S0033291718003057
ISSN: 0033-2917
Publisher: Cambridge University Press (CUP)
Start Page: 2186
End Page: 2196
Journal / Book Title: Psychological Medicine
Volume: 49
Issue: 13
Copyright Statement: © Cambridge University Press 2018 This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Keywords: Social Sciences
Science & Technology
Life Sciences & Biomedicine
Psychology, Clinical
Psychiatry
Psychology
Microglia
neuroinflammation
schizophrenia
TSPO
PERIPHERAL BENZODIAZEPINE-RECEPTOR
ULTRA-HIGH RISK
BINDING-SITES
TRANSLOCATOR PROTEIN
ANTIPSYCHOTIC TREATMENT
1ST-EPISODE PSYCHOSIS
ADULT SCHIZOPHRENIA
AUTOIMMUNE-DISEASES
CEREBROSPINAL-FLUID
18 KDA
Microglia
TSPO
neuroinflammation
schizophrenia
Psychiatry
1701 Psychology
1117 Public Health and Health Services
1109 Neurosciences
Publication Status: Published
Online Publication Date: 2018-10-25
Appears in Collections:Institute of Clinical Sciences